Kezar Life Sciences, Inc.
Kezar Life Sciences, Inc. (KZR): 4 pipeline candidates · ~27 mo cash runway · 10 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
26.8 months
D/E 0.04 · 0% dilution
Lead: Phase 1/Phase 2
4 candidates
N/A
N/A
A transparent, data-derived signal for Kezar Life Sciences, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$53.9M
Cash
$66.2M
Quarterly Burn
$7.4M
Runway
26.8 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| kzr-261 | Phase 1 |
| kzr-616 | Phase 1/Phase 2 |
| optimal medical therapy | — |
| zetomipzomib | Phase 2 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
41
Total value held
$29.7M
| Holder | Shares | Value |
|---|---|---|
| suvretta capital management, llc | 716,759 | $5.3M |
| tang capital management llc | 664,314 | $4.9M |
| vanguard capital management llc | 581,058 | $4.3M |
| rangeley capital, llc | 243,073 | $1.8M |
| affinity asset advisors, llc | 229,076 | $1.7M |
| susquehanna international group, llp | 201,600 | $1.5M |
| renaissance technologies llc | 188,426 | $1.4M |
| millennium management llc | 142,050 | $1.1M |
| ikarian capital, llc | 102,211 | $758K |
| blackrock, inc. | 100,064 | $742K |
Showing top 10 of 41 institutional holders of Kezar Life Sciences, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Kezar Life Sciences, Inc.'s pipeline?
Kezar Life Sciences, Inc. (KZR) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Kezar Life Sciences, Inc.'s lead drug candidate?
Kezar Life Sciences, Inc.'s most advanced tracked candidate is kzr-261 (Phase 1) for Advanced/Metastatic Solid Tumor.
What is Kezar Life Sciences, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Kezar Life Sciences, Inc. has approximately 26.8 months of cash runway.
What is Kezar Life Sciences, Inc.'s market capitalization?
Kezar Life Sciences, Inc.'s market capitalization is approximately $53.9M.
Who is the CEO of Kezar Life Sciences, Inc.?
Dr. Christopher J. Kirk Ph.D. is the chief executive officer of Kezar Life Sciences, Inc. (KZR).
Get the full picture on Kezar Life Sciences, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.